Allakos LLC, formerly known as Allakos Inc. is a biotechnology company. The Company is developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2025-05-14 EDT			5-day change	1st Jan Change
0.3291 ^USD	-0.06%		-.--%	-

25-05-15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
25-05-15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI

Market Cap	29.74M 25.86M 24.07M 22.1M 41.73M 2.84B 42.37M 284M 111M 1.41B 112M 109M 4.74B	P/E 2023	-1.28x	P/E 2024	-0.93x
Enterprise Value	-46.92M -40.79M -37.96M -34.86M -65.82M -4.48B -66.84M -447M -176M -2.23B -176M -172M -7.48B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	96.57%	Yield 2023 *	-	Yield 2024	-

25-05-15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
25-05-15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI
25-05-15	Allakos Inc. Announces Executive Changes	CI
25-05-14	Allakos Inc.(NasdaqGS:ALLK) dropped from NASDAQ Composite Index	CI
25-05-14	Concentra Biosciences, LLC completed the acquisition of Allakos Inc..	CI
25-05-08	Allakos Inc.(NasdaqGS:ALLK) dropped from S&P TMI Index	CI
25-05-07	Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-02	Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share	MT
25-04-02	Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences	RE
25-04-01	Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million.	CI
25-03-12	Allakos Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-03-12	Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
25-01-27	Top Midday Decliners	MT

24-01-17	Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	MT
24-01-17	JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	MT
24-01-17	Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
24-01-16	Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	MT
24-01-16	Lifesci Capital Downgrades Allakos to Market Perform From Outperform	MT

Allakos Inc. Stock

Stocks

ALLK

US01671P1003

Biotechnology & Medical Research

Valuation: Allakos Inc.

Latest news : Allakos Inc.

Analysts' recommendations: Allakos Inc.

Press Releases: Allakos Inc.

News in other languages: Allakos Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Allakos Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

22-07-22	Lonza-Aktien sinken nach Halbjahreszahlen
19-12-05	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
19-12-05	Des marchés moins cyclothymiques pour finir la semaine ?

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/15/25	Steven James	Issuer sale	Director	332,932	0.3726%
5/15/25	Neil Graham	Issuer sale	Director	195,786	0.2191%
5/15/25	BVF Partners LP	Issuer sale	Company	16,312,872	18.2586%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLAKOS INC.	-0.06%	-.--%	-.--%	-93.88%	29.74M
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+11.28%	48.53B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+403.17%	+614.40%	39.87B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+26.45%	+5.03%	38.68B
BEONE MEDICINES AG	-1.88%	-3.03%	+4.94%	+47.52%	35.13B
CELLTRION, INC.	-1.74%	+5.12%	+9.58%	+46.02%	29.79B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.08B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+35.09%	+127.95%	16.11B
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+1.25%	+8.92%	13.61B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-3.32%	-34.94%	12.62B
Average	-1.35%	+0.95%	+52.83%	+81.37%	25.05B
Weighted average by Cap.	-1.60%	+2.03%	+76.86%	+128.07%

	2023	2024
Net sales	-	-
Net income	-186M -161M -150M -138M -261M -17.73B -265M -1.77B -695M -8.83B -697M -682M -29.59B	-116M -101M -93.71M -86.04M -162M -11.06B -165M -1.1B -434M -5.5B -435M -425M -18.46B
Net Debt	-129M -112M -105M -96.08M -181M -12.35B -184M -1.23B -484M -6.15B -486M -475M -20.61B	-76.66M -66.64M -62.03M -56.95M -108M -7.32B -109M -731M -287M -3.64B -288M -282M -12.22B

3 years	0.22	5.64
5 years	0.22	112.87
10 years	0.22	157.98